Gene
RAD50
RAD50 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (2), Trial mentions (32), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention RAD50. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 8 of 11,460 | 0.07% |
| 2022 | 5 of 8,285 | 0.06% | 16 of 13,598 | 0.12% |
| 2021 | 7 of 8,692 | 0.08% | 19 of 15,045 | 0.13% |
| 2020 | 4 of 7,640 | 0.05% | 11 of 14,459 | 0.08% |
| 2019 | 1 of 7,300 | 0.01% | 10 of 12,159 | 0.08% |
| 2018 | 4 of 6,927 | 0.06% | 14 of 11,854 | 0.12% |
| 2017 | 2 of 6,558 | 0.03% | 11 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| New Amsterdam Genomics, Inc. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2020 |
| InVitae | Diagnostic provider | Clinical validation | 1 | February 20, 2019 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| RAD50 (L1237F) + ATM deletion | Irinotecan | response-associated | No disease recorded | Cancer Genome Interpreter |
| RAD50 (L1237F) + ATM deletion | Chk1/2 Inhibitor | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (32)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04706663 | Trial eligibility (AACT) |
| NCT04666740 | Trial eligibility (AACT) |
| NCT04187833 | Trial eligibility (AACT) |
| NCT03413995 | Trial eligibility (AACT) |
| NCT05967286 | Trial eligibility (AACT) |
Showing 5 of 32 trial mentions.
Target-disease associations (556)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to isolated 17,20 lyase deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY gonadal dysgenesis - motor and sensory neuropathy | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 556 associations.
Vendor sourcing (138)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | RAD50 | View trial NCT03061188 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The p.Q941* pathogenic mutation (also known as c.2821C>T), located in coding exon 17 of the RAD50 gene, results from a C to T substitution at nucleotide posi... | View ClinVar record SCV000053547.10 |
| Asan Medical Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and... | View trial NCT05222971 |
| Asan Medical Center | Trial sponsor | Mentioned in trial textTrial free-text mention | RAD50 | View trial NCT05222971 |
Showing 5 of 138 sourcing records.
Trial-cited literature (145)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | The Journal of clinical investigation | 2024 | 47 |
| Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. | JCO precision oncology | 2024 | 20 |
| Pathogenesis of allergic diseases and implications for therapeutic interventions. | Signal transduction and targeted therapy | 2023 | 286 |
Showing 5 of 145 papers.
Protein variant mentions (71)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A232D | 1 | 2015 | PMID 25741868 |
| p.A40V | 1 | 2015 | PMID 25741868 |
| p.C133F | 1 | 2015 | PMID 25741868 |
| p.D1065N | 1 | 2016 | PMID 26467025 |
| p.D1120H | 1 | 2015 | PMID 25503501 |
Showing 5 of 71 variants.
Literature-extracted relations (11)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Platinum | Chemical | associate |
Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy. | 2022 |
| Platinum | Chemical | associate |
Germline mutations of the DNA repair pathways in uterine serous carcinoma. | 2016 |
| Irinotecan | Chemical | associate |
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. | 2014 |
| GEMCITABINE | Chemical | associate |
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. | 2008 |
| Nucleosides | Chemical | associate |
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. | 2008 |
Showing 5 of 11 relation assertions.
Organizations publishing (263)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 13 | 2008 to 2023 |
| Government of the United States of America | Government | 8 | 2010 to 2021 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2014 to 2023 |
| Harvard Medical School | Academic | 5 | 2015 to 2018 |
| University of Copenhagen | Academic | 4 | 2014 to 2022 |
Showing 5 of 263 organizations.
Where RAD50 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
526 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.